Dernières nouvelles

Restez informé des développements actuels et des actualités de SMOB. Vous trouverez ici des mises à jour régulières sur des sujets passionnants et des événements importants qui touchent notre société professionnelle.

SMOB recommendations for prioritization of 2.4 mg Semaglutide therapy

Bernd Schultes1, Marco Bueter2,3, Lucie Favre4,5,6, Katharina Timper7,8 for the collaborative task force “prioritization of anti-obesity pharmacotherapy” of the Swiss Society for the Study of Morbid Obesity and Metabolic Disorders (SMOB) Background The current limited availability of the GLP-1 receptor agonist (GLP-1 RA) product Wegovy® (2.4 mg semaglutide) demands a prioritization by means of which […]


SMOB statement for the world obesity day 2024

To our Patients,To the loved ones of people living with obesity,To our Colleagues in healthcare, Obesity care has seen considerable improvements in the past years. Pharmacotherapy and bariatric-metabolic surgery can now offer several treatment options that are secure and efficient.However, as it often happens when medical progress evolves fast, good practice recommendations and treatments with […]